Sandra Calvin - 15 Sep 2021 Form 3 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role
VP, Corp Controller and CAO
Signature
/s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol
TVTX
Transactions as of
15 Sep 2021
Net transactions value
$0
Form type
3
Filing time
23 Sep 2021, 18:14:24 UTC
Next filing
26 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TVTX Common Stock 28,754 15 Sep 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 30,000 $12.67 Direct F1
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 5,000 $32.49 Direct F1
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 10,000 $16.23 Direct F1
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 10,000 $17.44 Direct F1
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 10,000 $25.25 Direct F2
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 10,000 $17.96 Direct F3
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 15,000 $15.46 Direct F4
holding TVTX Employee Stock Option (Right to Buy) 15 Sep 2021 Common Stock 17,500 $26.88 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 One-fourth of the shares subject to the stock option vested and become exercisable on May 10, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
F3 One-fourth of the shares subject to the stock option vested and become exercisable on May 9, 2020, and the remaining shares vest in 36 equal monthly installments thereafter.
F4 One-fourth of the shares subject to the stock option vested and become exercisable on January 31, 2021, and the remaining shares vest in 36 equal monthly installments thereafter.
F5 One-fourth of the shares subject to the stock option will vest and become exercisable on January 21, 2022, and the remaining shares vest in 36 equal monthly installments thereafter.